CD19-CAR T cells reset the EBV + autoreactive B cell repertoire in autoimmune disease
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. 1–4 Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy 5–7 is unknown. Here, using EBV B-cell sequencing (EBV-seq) 3 , we profiled EBV + B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV + B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV + B cells and shifted the reconstituted repertoire towards IgM + , minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV + B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro , EBV + B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV + autoreactive B-cell repertoire contributes to sustained drug-free remission.
Article activity feed
-
Source: www.biorxiv.org/content/10.6... Full study (PDF): www.biorxiv.org/content/10.6...
-
CD19-CAR T cells clear the EBV-infected B cells that carry autoreactive antibodies. Rituximab doesn’t. That may be why only one of them produces lasting remission. New Robinson Lab preprint led by me and Mahesh Pandit. 🧵 www.biorxiv.org/content/10.6...
-
Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab. 8 of 12 CAR T-cell patients achieved sustained drug-free remission. www.biorxiv.org/content/10.6...
-
CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1
-
CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1
-
-